Logotype for GMM Pfaudler Limited

GMM Pfaudler (505255) Q1 26/27 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for GMM Pfaudler Limited

Q1 26/27 earnings summary

10 Aug, 2026

Executive summary

  • Completed a major organizational transformation, shifting from regional to four global technology divisions (CRT, PPT, HET, PST) with dedicated leadership and accountability for technology, product, and customer engagement.

  • Revenue grew 16% year-over-year to ₹925 crore, with EBITDA at ₹94 crore (down 7% YoY), and PAT at ₹23.90 crore (up over 100% YoY).

  • Order intake reached ₹1,007 crore, flat YoY but up 16% QoQ, and backlog increased 20% YoY to ₹2,289 crore.

  • Leadership team strengthened, with clear roles and succession planning to drive global mindset and performance alignment.

  • Major orders secured in mining and petrochemical sectors, strengthening diversification.

Financial highlights

  • Consolidated revenue for Q1 FY 2027 was ₹924.76 crore, up 16% year-on-year.

  • EBITDA stood at ₹94 crore, down 7% YoY but up 25% sequentially; EBITDA margin was 10.1%, down from 12.7% YoY but up from 8.0% sequentially.

  • Profit After Tax was ₹23.90 crore, more than doubling year-on-year; PAT margin improved to 2.4% from 1.3% YoY.

  • Basic EPS rose 114% YoY to ₹5.32.

  • Order backlog reached ₹2,289 crore, up 20% YoY and 4% QoQ, with most orders executable within FY 2027.

Outlook and guidance

  • Management targets a minimum 15% EBITDA margin over the medium term, with ongoing initiatives to improve margins and cost structure.

  • Margin improvement expected as underperforming units are addressed and integration synergies are realized.

  • Positive momentum expected to continue, supported by a healthy order pipeline and strong backlog.

  • Ongoing initiatives to reduce debt and optimize capital structure, with EUR 7 million debt repayment planned by Q2 FY27.

  • Strong revenue visibility for FY 2027 due to robust order backlog and improving market conditions, especially in pharma.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more